Liver-specific inhibitor ND-654, which mimics ACC phosphorylation, inhibits liver DNL and the progression of HCC, resulting in an improved prognosis for tumour-bearing mice (73). This evidence concerns the gene ACACA and hepatocellular carcinoma.